| Literature DB >> 31774807 |
Eric B Loucks1,2,3, William R Nardi1,2, Roee Gutman4, Ian M Kronish5, Frances B Saadeh1, Yu Li1, Anna E Wentz1, Julie Webb2, David R Vago6, Abigail Harrison2, Willoughby B Britton2,7.
Abstract
BACKGROUND AND OBJECTIVES: Impacts of mindfulness-based programs on blood pressure remain equivocal, possibly because the programs are not adapted to engage with determinants of hypertension, or due to floor effects. Primary objectives were to create a customized Mindfulness-Based Blood Pressure Reduction (MB-BP) program, and to evaluate acceptability, feasibility, and effects on hypothesized proximal self-regulation mechanisms. Secondary outcomes included modifiable determinants of blood pressure (BP), and clinic-assessed systolic blood pressure (SBP).Entities:
Mesh:
Year: 2019 PMID: 31774807 PMCID: PMC6881004 DOI: 10.1371/journal.pone.0223095
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Theoretical framework of mechanisms through which Mindfulness-Based Blood Pressure Reduction (MB-BP) program may influence blood pressure.
Fig 2CONSORT flow diagram for the MB-BP study participation.
Demographic characteristics of sample at baseline (n = 48).
Please refer to Table 2 for determinants of blood pressure levels at baseline.
| Variable | Point Estimate |
|---|---|
| Age, y | 60.0 |
| Race, % White | 95.9 |
| Gender, % women | 61.2 |
| Education, % college education | 91.8 |
| Hypertension Status | |
| Uncontrolled stage 2 hypertension, % | 47.9 |
| Stage 1 hypertension, % | 33.3 |
| Elevated blood pressure, % | 18.8 |
| Taking antihypertensive medication, % | 60.4 |
Stage 2 hypertension: SBP≥140 or DBP≥90 mmHg; Stage 1 hypertension: 130≤SBP<140 or 80≤DBP<90 mmHg; Elevated blood pressure: 120≤SBP<130 mmHg and DBP<80 mmHg. DBP, diastolic blood pressure; SBP, systolic blood pressure. Note that "uncontrolled" stage 2 hypertension reflects participants with SBP≥140 or DBP≥90 mmHg at baseline. Some participants in stage 1 hypertension or elevated blood pressure categories may have been in Stage 2 hypertension in the past, but may be currently controlled by antihypertensive medication or nonpharmacologic interventions.
Secondary outcomes, representing evidence-based determinants of blood pressure that are intermediate MB-BP intervention targets.
| Baseline | 3 months | 6 months | 12 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Point Estimate | 95% CI | n | Point Estimate | 95%^ CI | p | n | Point Estimate | 95% CI | p | n | Point Estimate | 95% CI | p | ||
| Body Mass Index | All participants, mean | 48 | 28.5 | 27.2, 29.7 | 44 | 28.2 | 26.9, 29.5 | 41 | 28.3 | 27.0, 29.6 | 0.33 | 43 | 28.6 | 27.3, 29.9 | 0.377 | |
| Participants with BMI ≥25 kg/m2 at baseline, mean | 40 | 29.5 | 28.2, 30.8 | 37 | 29.2 | 27.9, 30.5 | 34 | 29.4 | 28.1, 30.7 | 0.43 | 36 | 29.7 | 28.4, 31.0 | 0.285 | ||
| DASH Diet Score | All participants, mean | 48 | 3.27 | 3.02, 3.52 | 44 | 3.49 | 3.24, 3.75 | 0.15 | 41 | 3.42 | 3.15, 3.68 | 0.35 | 43 | 3.41 | 3.15, 3.67 | 0.370 |
| Participants with DASH diet score <5.5 at baseline, mean | 32 | 2.78 | 2.51, 3.06 | 29 | 3.38 | 3.10, 3.67 | 26 | 3.37 | 3.08, 3.67 | 28 | 3.34 | 3.05, 3.63 | ||||
| Sodium Intake, Added at Table (shakes per day) | All participants, mean | 48 | 0.69 | 0.36, 1.01 | 43 | 0.38 | 0.06, 0.72 | 43 | 0.41 | 0.08, 0.74 | 42 | 0.46 | 0.13, 0.79 | |||
| Participants consuming >1500 mg/d at baseline, mean | 10 | 1.63 | 0.61, 2.65 | 8 | 0.43 | -0.63,1.50 | 8 | 0.54 | -0.52,1.61 | 8 | 0.55 | -0.52,1.61 | ||||
| Aerobic Physical Activity | All participants, % adhering to AHA physical activity guidelines | 48 | 69% | 54%, 80% | 44 | 66% | 51%, 78% | 0.77 | 43 | 65% | 50%, 78% | 0.71 | 43 | 70% | 55%, 82% | 0.916 |
| Participants not adhering to AHA physical activity guidelines at baseline, | 15 | 0% | NA | 14 | 29% | 11%, 57% | 13 | 38% | 17%, 66% | 14 | 29% | 11%, 57% | ||||
| Flexibility Activities | All participants, % engaging in flexibility activities | 48 | 42% | 29%, 56% | 44 | 73% | 58%, 84% | 43 | 63% | 48%, 76% | 43 | 60% | 45%, 74% | 0.073 | ||
| Participants not engaging in flexibility activities at baseline, % adherence | 28 | 0% | NA | 28 | 57% | 38%, 74% | 26 | 42% | 25%, 62% | 27 | 41% | 24%, 60% | ||||
| Muscle Strengthening Activities | All participants, % engaging in muscle strengthening | 48 | 38% | 25%, 52% | 44 | 41% | 27%, 56% | 0.74 | 43 | 44% | 30%, 59% | 0.52 | 43 | 37% | 24%, 52% | 0.980 |
| Participants not engaging in muscle strengthening at baseline, % adherence | 31 | 0% | NA | 29 | 21% | 10%, 39% | 27 | 26% | 13%, 46% | 28 | 14% | 5%, 33% | ||||
| Daily Alcohol Consumption | All participants, mean number of drinks per day | 47 | 0.64 | 0.41, 0.86 | 43 | 0.53 | 0.30, 0.76 | 0.06 | 42 | 0.51 | 0.27, 0.74 | 43 | 0.56 | 0.33, 0.80 | 0.200 | |
| Mean number of drinks per day in participants not adhering to AHA guidelines at baseline | 7 | 2.61 | 1.95, 3.27 | 6 | 1.75 | 1.05, 2.45 | 5 | 1.41 | 0.68, 2.14 | 5 | 1.72 | 1.02, 2.42 | ||||
| Binge Drinking | All participants, mean binge drinking days in past 30 days | 46 | 0.8 | 0.2, 1.4 | 29 | 0.3 | -0.4, 0.9 | 0.08 | 29 | 0.6 | -0.1, 1.3 | 0.55 | 34 | 0.3 | -0.4, 0.9 | 0.060 |
| Mean binge drinking days in past 30 days, only in participants binge drinking at baseline | 8 | 4.5 | 2.0, 7.0 | 6 | 1.7 | -1.1, 4.5 | 5 | 3.3 | 0.3, 6.2 | 0.37 | 6 | 1.5 | -1.2, 4.3 | |||
| Perceived Stress Scale | All participants, mean | 48 | 22.7 | 20.7, 24.8 | 42 | 20.1 | 18.2, 22.4 | 43 | 20.0 | 17.9, 22.1 | 42 | 20.7 | 18.6, 22.8 | |||
| Participants with PSS score greater than US mean of 16, mean | 40 | 24.3 | 22.6, 25.9 | 25 | 23.9 | 22.0, 25.8 | 0.67 | 28 | 22.8 | 21.0, 24.6 | 0.09 | 28 | 23.3 | 21.5, 25.1 | 0.280 | |
| Directly assessed from participants’ medication bottles | Increased antihypertensive medication dose and/or added additional antihypertensive medication type, % | NA | NA | NA | 2 | 7.7 | 1.8, 27.5 | 0.15 | 3 | 12.5 | 3.8, 33.9 | 0.07 | 3 | 11.5 | 3.6, 31.6 | 0.074 |
| Decreased antihypertensive medication dose and/or removed antihypertensive medication type, % | NA | NA | NA | 2 | 7.7 | 1.8, 27.5 | 0.15 | 4 | 16.7 | 6.1, 38.3 | 3 | 11.5 | 3.6, 31.6 | 0.074 | ||
| Changed antihypertensive medication type, % | NA | NA | NA | 3 | 11.5 | 3.6, 31.6 | 0.07 | 3 | 12.5 | 3.8, 33.9 | 0.07 | 5 | 19.2 | 7.9, 39.9 | ||
| Directly assessed via eCAPs | Percent adherence to antihypertensive medication assessed via eCAPS, % | 16 | 0.95 | 0.90, 0.99 | 16 | 0.87 | 0.82, 0.93 | 0.004 | 16 | 0.91 | 0.88, 0.94 | 0.15 | 16 | 0.91 | 0.88, 0.94 | 0.190 |
*AHA guidelines consistent with RAPA are engaging in 30 minutes or more per day of moderate physical activities 5 or more days per week, or 20 minutes or more per day of vigorous physical activities 3 or more days per week
**AHA guidelines for alcohol consumption are < = 2 drinks per day for males and < = 1 drink per day for females
Analyses were performed using hierarchical linear models. P values represent comparison of respective follow-up time to baseline
Primary outcomes at baseline through 1-year follow-up, representing proximal MB-BP intervention targets.
| Baseline | 3 months | 6 months | 1 year | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Point Estimate | 95 CI | n | Point Estimate | 95 CI | p | n | Point Estimate | 95% CI | p | n | Point Estimate | 95% CI | p | |
| Difficulties in Emotion Regulation Scale, mean score | 48 | 70.4 | 65.0, 75.8 | 41 | 67.7 | 62.1, 73.3 | 0.23 | 43 | 65.7 | 60.1, 71.3 | 41 | 65.1 | 59.5, 70.8 | ||
| Multidimensional Assessment of Interoceptive Awareness, mean score | 35 | 22.6 | 20.8, 24.4 | 37 | 26.3 | 24.6, 28.1 | 38 | 26.3 | 24.5, 28.0 | 35 | 26.4 | 24.6, 28.1 | |||
| Sustained Attention to Response Task, % correct no-go | 42 | 69.5 | 65.1, 73.9 | 43 | 75.9 | 71.6, 80.2 | 36 | 76.4 | 71.9, 81.0 | 41 | 79.0 | 74.6, 83.4 | |||
Analyses were performed using hierarchical linear models. P values represent comparison of respective follow-up time to baseline.
Fig 3Changes in systolic blood pressure (SBP) from baseline through follow-up after MB-BP intervention.
Analyses were performed using hierarchical linear models. P-values represent comparison of respective follow-up time to baseline. Error bars are standard errors of the mean. Error bars represent standard error of the mean. P-values compare follow-up times to baseline. Sample sizes for comparisons at 3, 6 and 12 months vs. baseline are 20, 18, and 19, respectively, for participants with SBP≥140, and 24, 23, and 24, respectively, for participants with SBP≥120 and <140 mmHg.
Fig 4Mean systolic blood pressure (SPB) over one-year follow-up, stratified by tertile of formal home mindfulness practice amount during the eight week MB-BP course.
Analyses were performed using hierarchical linear models. P-values represent comparison of respective follow-up time to baseline. Error bars are standard errors of the mean. Sample sizes for comparisons at 3, 6 and 12 months vs. baseline are 14, 13 and 11 respectively, for highest tertile of home practice, 15,14, and 14, respectively, for participants with medium tertile of home practice, and 15, 14, and 14, respectively, for participants with lowest tertile of home practice.